<sup>131</sup>I治疗甲亢后致甲减的研究变迁

陈再君; 蒋宁一

¹³¹I治疗甲亢后致甲减的研究变迁

陈再君 , 蒋宁一

文章导航 > 国际放射医学核医学杂志 > 2004, 28 > 4: (153-157)

引用本文:

Citation:

¹³¹I治疗甲亢后致甲减的研究变迁

陈再君¹,
蒋宁一²

1. 421002 衡阳, 南华大学附属南华医院核医学科;
2. 510120 广州, 中山大学附属第二医院核医学科
中图分类号: R581.2;R817

The research vicissitudes of hypothyroidism after ¹³¹I therapy for hyperthyroidism

CHEN Zai-jun¹,
JIANG Ning-yi²

1. Department of Nuclear Medicine, the Affiliated Nan Hua Hospital, Nan Hua University, Hengyang 421002, China;
2. Department of Nuclear Medicine, the Second Affiliated Hospital of Zhongshan Uni-versity, Guangzhou 510120, China
CLC number: R581.2;R817

摘要: 回顾性分析半个多世纪以来已发表的¹³¹I治疗甲状腺功能亢进症(甲亢)后甲状腺功能减退症(甲减)的随访资料,旨在探讨¹³¹I治疗甲亢后甲减的发生率、影响甲减的相关因素及有待进一步研究的问题。
- 甲状腺功能亢进症 /
- 甲状腺功能减退症 /
- 碘放射性同位素 /
- 放射治疗
Abstract: A Retrospective analysis of hypothyroidism data after iodine-131 therapy for hyperthy-roidism during about 60-year period was performed. The aim of this work was to discuss incidence of hypothyroidism occurring after iodine-131 therapy for hyperthyroidism, influence factors of hypothyroidism and farther investigative problem.
- hyperthyroidism /
- hypothyroidism /
- iodine Iadioisotopes /
- radiotherapy
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Uy HL,Reasner CA,Samuels MH.Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves disease[J Am J Med,1995,99:173-179.
[2]	Giovanella L,D e palma D,Ceriani L,et al.Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach:Clinical results[J].Radiol Med(Torino),2000,100(6):480-483.
[3]	Andrade VA,Gross JL,Maia AL.The effect of mothimazole pretreatment on the efficaly of radioactive iodine therapy in Graves' hyperthyroidism:one-year of follow-up of a prospective,randomized study[J].J Clin Endocrinol M etab,2001,8(8):3488-3493.
[4]	Ghadban WK,Zirie MA,AL-Khateeb DA,et al.Radioiodine treatment of hyperthyroidism:success rate and influence of thyrostaticm edication[J].Saudi Med J,2003,24(4):347-351.
[5]	Ahmad AM,Ahmad M,Young ET.Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis[J].Eur J Endocrinol,2002,146(6):767-775.
[6]	Gomez JM,Gomez N,Amat M,et al.Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism[J].Ann Endocrinol(paris),2000,61(3):184-191.
[7]	Holm LE,Lundell G,Israesson A,et al.Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthy-roidism[J].J Nucl Med,1982,23(2):103-107.
[8]	Bringmann IM,Van leeuwen BL,Hennemann G,et al.Outcome of treatment of hyperthyroidism[J].J Endocrinol Invest,1999,22(4):250-256.
[9]	Yoshimoto M,Iino S,Yoshimura H,et al.A five-year follow-up of two different ¹³¹I treatment methods for Graves' disease and the factors affecting the outcome[J].J Nippon Naibupi Gakkai Zasshi,1998,70(9):995-1006.
[10]	Gomez N,Gomez JM,Orti A,et al.Transient hypothyroidism af-teriodine-131 therapy for Graves' disease[J].J Nucl Med,1995,36(9):1539-1542.
[11]	Sabri O,Schulz G,Zimny M,et al.Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients radioactive iodine with Graves' disease[J].Nuklearmedizin,1998,37:83-84.
[12]	Sabri O,Zimny M,Schreekenbergerm,et al.Characterization of the rapy failures in radioidine therapy of Grave's disease without antithyroid agents[J].Nuklearmedizin,2001,40(1):1-6.
[13]	Gibold L,Delisle MJ,Maes B.Treatment of hyperthyroidism by radioactive iodine:Development of methods and difficulties in the surveillance[J].Presse Med,1988,17(17):1397-1400.
[14]	Lesie W D,Peterely AE,Dupout JD.Radioiodine therapy treatment in thyroid glands previously irradiated for Graves' hyperthyroidism[J].J Nucl Med,1998,39(4):712-716.
[15]	Chiovato L,Fiore E,Vitti P,et al.Outcome of thyroid function in Grave's patient with radioidin:role of thyroid-stimulating and thyrotropin-blocking antibodies and radioiodine-induced thyriod dam-age[J].J Clin Endocrinol Meted,1998,83(1):40-46.

[1]	李诗运 . ¹³¹I治疗甲亢后甲减的综合预防和处理措施. 国际放射医学核医学杂志, 2004, 28(4): 157-159.
[2]	陈美言 , 李雪娜 , 李亚明 . Graves甲亢¹³¹I治疗后甲状腺功能的变化特点及其与治疗前抗体水平的关系. 国际放射医学核医学杂志, 2021, 45(1): 18-23. doi: 10.3760/cma.j.cn121381-202003035-000015
[3]	陈丹云 , 静进 . 甲状腺功能亢进症治疗方法的选择. 国际放射医学核医学杂志, 2007, 31(4): 228-231.
[4]	潘香颖 , 李慧贞 . 甲状腺功能亢进症伴肝功能受损的¹³¹I治疗疗效. 国际放射医学核医学杂志, 2009, 33(3): 179-180. doi: 10.3760/cma.j.issn.1673-4114.2009.03.013
[5]	冯菲 , 赵德善 . ¹³¹I治疗青少年儿童甲状腺功能亢进症. 国际放射医学核医学杂志, 2009, 33(3): 171-174,183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.011
[6]	汤建林 , 李玉莹 , 高柳艳 , 唐秀萍 , 胡红永 . 甲状腺功能亢进症治疗方法的比较和选择. 国际放射医学核医学杂志, 2009, 33(3): 175-178. doi: 10.3760/cma.j.issn.1673-4114.2009.03.012
[7]	董华 , 刘东海 , 李亚男 , 胡海龙 , 张遵城 . 肿瘤免疫治疗致甲状腺功能异常的⁹⁹Tc^mO₄⁻ SPECT显像分析及文献复习. 国际放射医学核医学杂志, 2021, 45(9): 607-610. doi: 10.3760/cma.j.cn121381-202004017-00103
[8]	郭坤 , 高蕊 , 于燕 , 刘岩 , 杨爱民 . 表皮生长因子受体基因表达与甲状腺功能亢进症¹³¹I治疗预后的关系. 国际放射医学核医学杂志, 2015, 39(1): 4-8. doi: 10.3760/cma.j.issn.1673-4114.2015.01.003
[9]	苏莉 , 陈璟 , 赵明 . ¹³¹I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较. 国际放射医学核医学杂志, 2007, 31(6): 366-369.
[10]	王长修 . 甲状腺功能亢进症患者再次¹³¹I治疗的给药剂量对比研究. 国际放射医学核医学杂志, 2009, 33(3): 182-183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.016